NY-KYNDRYL
Kyndryl (NYSE: KD), the world's largest IT infrastructure services provider, today announced a new open integration platform giving business leaders real-time insights into their complex IT estates, and unprecedented control over customizing their mission-critical operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005855/en/
Kyndryl Introduces New Platform, Kyndryl Bridge, to Orchestrate IT Estates and Drive Business Growth (Graphic: Business Wire)
Kyndryl Bridge leverages Kyndryl’s core technology strengths. It marshals decades of expertise, operational data patterns and IP to generate actionable insights that redefine how enterprises improve and accelerate their AI-powered analytics and business objectives. In doing so, it creates an uninterrupted path between digital business and the tech that drives it. Kyndryl Bridge is designed to meet customers where they are today, enabling interoperability that maximizes the value of tools they already know and trust.
“Dealing with complexity is what Kyndryl does best, and what customers need most. Kyndryl Bridge will be a way for our customers, and Kyndryl, to run their mission-critical infrastructure and digital transformation journeys better,” said Martin Schroeter, Kyndryl’s Chairman and Chief Executive Officer. “Kyndryl is committed to transforming how IT services are delivered, and Kyndryl Bridge is core to our long-term strategic mission to grow our ecosystem of alliance partners, use tools and IP to create a robust advanced delivery system, and ultimately dedicate more expertise and focus to best serve customers at scale.”
Across the global economy, digital modernization efforts sit at the top of today’s business agendas, with 60 percent of CIOs citing it as their most critical growth driver in 2022. However, business and technology complexity — along with a shortage of critical IT skills — has slowed progress for most enterprises. Kyndryl is accelerating its customers’ digital business journeys by innovating to deliver solutions through platform-enabled services.
“Enterprise IT leaders today are responsible for the management of increasingly-complex IT estates that demand greater oversight, interoperability, and AI-powered analytics to avert challenges and downtime,” says David Tapper, program VP, Outsourcing and Managed Cloud Service at IDC. “The ability of Kyndryl Bridge to connect the many tools, workflows, and processes in which enterprises have spent years investing, while delivering real-time, actionable insights and recommendations, is a powerful proposition for enterprises throughout the global economy.”
Kyndryl Bridge integrates and connects the complex management and process tools that enterprises throughout the global economy rely upon. Its capabilities have, on average, reduced the number of incidents per server per month for enterprises by 74 percent.
“By enabling leaders to focus less on managing IT systems, they can build and support their digital business strategies while freeing up IT resources for higher-value work,” said Antoine Shagoury, Kyndryl’s Chief Technology Officer. “It provides greater access and control over critical tools, and Kyndryl experts in cloud, data and AI, security and resiliency, mainframe modernization, and other important aspects of the IT estate.”
Designed with configurability in mind, Kyndryl Bridge is evolving to deploy ready-made, industrial scale solutions from Kyndryl and its broad and growing partner ecosystem. Its intelligent management tools, powered by automation and AI, will provide technology leaders with real-time insights to prevent downtime and better forecast future needs and costs.
“As customers accelerate their digital transformation, Kyndryl’s new digital integration platform can help provide rich data insights, solutions automation, and services delivery expertise,” said Nick Holden, Vice President, Cisco Global Strategic Partners and Co-sell. “Kyndryl Bridge is a big step forward to enable Kyndryl and Cisco to deliver business outcomes that our joint customers are demanding.”
For customers, the platform maximizes the benefits of native multi-cloud capabilities and delivers an ‘as-a-service’ (aaS) operating environment. It is designed to be a strategic digital hub, that will continue to expand and grow over time, connecting Kyndryl’s advanced technology and tooling with a deep bench of industry expertise and forward-thinking innovators across virtually every sector of the global economy.
About Kyndryl
Kyndryl (NYSE: KD) is the world’s largest IT infrastructure services provider serving thousands of enterprise customers in more than 60 countries. The Company designs, builds, manages, and modernizes the complex, mission-critical information systems that the world depends on every day. For more information, visit www.kyndryl.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
